UnitedHealth (UNH) Stock Rated Outperform Despite Lowered Price Target by Leerink

Leerink Partners maintained its Outperform rating on UnitedHealth Group (UNH) but lowered its price target from $355 to $340, citing "moderately fading" investor expectations for the company's 2025 financial forecast. The firm suggests that 2025 EPS guidance within the $18-$19 range would alleviate current market worries and establish a foundation for a multi-year margin expansion story, with growth potentially accelerating by 2027.

Analysis

Leerink Partners has maintained its Outperform rating on UnitedHealth Group (UNH) but lowered its price target to $340 from $355, reflecting a cautious stance driven by "moderately fading" investor expectations. The key catalyst is the company's anticipated 2025 financial forecast, which has not yet been reinstated. According to the analyst note, the market is focused on a 2025 earnings per share (EPS) guidance in the range of $18 to $19. Achieving this range is critical as it would likely soothe investor concerns regarding the "materiality of the reduction in overall margins." Successfully meeting this expectation would not only stabilize near-term sentiment but also establish the foundation for a "multi-year margin story," with potential for growth acceleration in 2027 as the company moves past its V28 initiative.

Key Decisions for Investors

• Investors should closely monitor UnitedHealth's upcoming 2025 financial guidance, as an EPS forecast within the $18-$19 range is the key catalyst needed to alleviate margin concerns and validate the firm's 'Outperform' thesis.
• Given the lowered price target and cautious sentiment, the stock may remain range-bound until the guidance is released, so investors should be prepared for potential near-term volatility or sideways movement.
• For long-term investors, any share price weakness prior to the guidance announcement could be viewed as a strategic entry opportunity, contingent on the belief that management will deliver a forecast that initiates the potential multi-year margin recovery.